Purchase this article with an account.
J.–E. Chang–Lin, W. Way, S. Matsumoto, A. Vickers, D. Tang–Liu, R. Schiffman, D. Welty; Cytotoxicity Comparison of the Fourth–Generation Fluoroquinolones Gatifloxacin and Moxifloxacin in Primary Rabbit Corneal Epithelial Cell Layers Using an Ethidium Bromide Staining Assay . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4882.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To compare the cytotoxicity upon the rabbit corneal epithelial cell layers (RCECL) of gatifloxacin (Zymar®) versus moxifloxacin (VigamoxTM) using an ethidium bromide staining assay Methods: Corneal epithelial cells were harvested from New Zealand White rabbit cornea and cultured on TranswellTM filters until confluency (Day 5–6) according to an established method. Cytotoxicity assessment of RCECL was conducted with Zymar® (0.3% gatifloxacin preserved with 0.0005% benzalkonium chloride [BAK], Allergan, Inc.) and VigamoxTM (0.5% moxifloxacin, unpreserved, Alcon Laboratories, Inc.) by ethidium bromide staining. Fluoroquinolone solutions were applied to the apical compartment (tear side) of the Transwells containing RCECL and cells were incubated at 37oC for 15 and 30 min. Results:In the 30 min cytotoxicity studies with marketed fluoroquinolones, VigamoxTM resulted in 3.0 x greater cytotoxicity compared to Zymar® (p<0.001). Similarly, a 15 min treatment to the apical compartment of RCECL resulted in 2.8 x greater cytotoxicity of VigamoxTM compared to that of Zymar® (p<0.001). Conclusions: Despite the presence of BAK, Zymar® resulted in significantly lower cytotoxicity and cell membrane disruption, as measured by ethidium bromide staining, compared to VigamoxTM. These results are consistent with recently reported in–vitro and clinical results.
This PDF is available to Subscribers Only